Does the phase of menstrual cycle affect MR-guided focused ultrasound surgery of uterine leiomyomas?

Minna J. So, Fiona M. Fennessy, Kelly H. Zou, Nathan McDannold, Kullervo Hynynen, Ferenc A. Jolesz, Elizabeth A Stewart, Frank J. Rybicki, Clare M. Tempany

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: To determine whether the phase of menstrual cycle at the time of MR-guided focused ultrasound surgery (MRgFUS) treatment for uterine leiomyomas affects treatment outcome. Methods: We enrolled all patients participating in a prospective phase III clinical trial from our center who completed 6 months of clinical and imaging follow-up. Patients with irregular cycles and those on oral contraceptives were excluded. Data prospectively documenting the date of the last menstrual period (LMP) at the time of treatment, length and duration of cycle, and raw symptom severity score (SSS) from the Uterine Fibroid Symptom and Quality of Life questionnaire, at baseline and 6 months were collected. Proliferative phase patients were determined retrospectively as those who were treated within less than 14 days from LMP; secretory phase patients were classified as those who were treated greater than 14 days from LMP. Results: A total of 58 patients were enrolled. There was no significant difference in the mean SSS at baseline and mean SSS at 6 months between patients treated in the proliferative versus secretory phase of the cycle. No significant difference in the SSS change from baseline to 6 months was seen between the two groups. Conclusions: Menstrual cycle phase does not influence MRgFUS treatment outcome. Symptomatic improvement occurs with treatment during either phase of the menstrual cycle. Thus, the scheduling of MRgFUS treatment need not be based upon the phase of the menstrual cycle.

Original languageEnglish (US)
Pages (from-to)203-207
Number of pages5
JournalEuropean Journal of Radiology
Volume59
Issue number2
DOIs
StatePublished - Aug 2006
Externally publishedYes

Fingerprint

Leiomyoma
Menstrual Cycle
Phase III Clinical Trials
Luteal Phase
Therapeutics
Oral Contraceptives
Quality of Life

Keywords

  • Fibroids
  • Focused ultrasound
  • Leiomyomas
  • Menstrual cycle
  • MRgFUS

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

So, M. J., Fennessy, F. M., Zou, K. H., McDannold, N., Hynynen, K., Jolesz, F. A., ... Tempany, C. M. (2006). Does the phase of menstrual cycle affect MR-guided focused ultrasound surgery of uterine leiomyomas? European Journal of Radiology, 59(2), 203-207. https://doi.org/10.1016/j.ejrad.2006.05.004

Does the phase of menstrual cycle affect MR-guided focused ultrasound surgery of uterine leiomyomas? / So, Minna J.; Fennessy, Fiona M.; Zou, Kelly H.; McDannold, Nathan; Hynynen, Kullervo; Jolesz, Ferenc A.; Stewart, Elizabeth A; Rybicki, Frank J.; Tempany, Clare M.

In: European Journal of Radiology, Vol. 59, No. 2, 08.2006, p. 203-207.

Research output: Contribution to journalArticle

So, MJ, Fennessy, FM, Zou, KH, McDannold, N, Hynynen, K, Jolesz, FA, Stewart, EA, Rybicki, FJ & Tempany, CM 2006, 'Does the phase of menstrual cycle affect MR-guided focused ultrasound surgery of uterine leiomyomas?', European Journal of Radiology, vol. 59, no. 2, pp. 203-207. https://doi.org/10.1016/j.ejrad.2006.05.004
So, Minna J. ; Fennessy, Fiona M. ; Zou, Kelly H. ; McDannold, Nathan ; Hynynen, Kullervo ; Jolesz, Ferenc A. ; Stewart, Elizabeth A ; Rybicki, Frank J. ; Tempany, Clare M. / Does the phase of menstrual cycle affect MR-guided focused ultrasound surgery of uterine leiomyomas?. In: European Journal of Radiology. 2006 ; Vol. 59, No. 2. pp. 203-207.
@article{4fca2ec75dfa44e289fc57cc96803e6d,
title = "Does the phase of menstrual cycle affect MR-guided focused ultrasound surgery of uterine leiomyomas?",
abstract = "Purpose: To determine whether the phase of menstrual cycle at the time of MR-guided focused ultrasound surgery (MRgFUS) treatment for uterine leiomyomas affects treatment outcome. Methods: We enrolled all patients participating in a prospective phase III clinical trial from our center who completed 6 months of clinical and imaging follow-up. Patients with irregular cycles and those on oral contraceptives were excluded. Data prospectively documenting the date of the last menstrual period (LMP) at the time of treatment, length and duration of cycle, and raw symptom severity score (SSS) from the Uterine Fibroid Symptom and Quality of Life questionnaire, at baseline and 6 months were collected. Proliferative phase patients were determined retrospectively as those who were treated within less than 14 days from LMP; secretory phase patients were classified as those who were treated greater than 14 days from LMP. Results: A total of 58 patients were enrolled. There was no significant difference in the mean SSS at baseline and mean SSS at 6 months between patients treated in the proliferative versus secretory phase of the cycle. No significant difference in the SSS change from baseline to 6 months was seen between the two groups. Conclusions: Menstrual cycle phase does not influence MRgFUS treatment outcome. Symptomatic improvement occurs with treatment during either phase of the menstrual cycle. Thus, the scheduling of MRgFUS treatment need not be based upon the phase of the menstrual cycle.",
keywords = "Fibroids, Focused ultrasound, Leiomyomas, Menstrual cycle, MRgFUS",
author = "So, {Minna J.} and Fennessy, {Fiona M.} and Zou, {Kelly H.} and Nathan McDannold and Kullervo Hynynen and Jolesz, {Ferenc A.} and Stewart, {Elizabeth A} and Rybicki, {Frank J.} and Tempany, {Clare M.}",
year = "2006",
month = "8",
doi = "10.1016/j.ejrad.2006.05.004",
language = "English (US)",
volume = "59",
pages = "203--207",
journal = "Journal of Medical Imaging",
issn = "0720-048X",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Does the phase of menstrual cycle affect MR-guided focused ultrasound surgery of uterine leiomyomas?

AU - So, Minna J.

AU - Fennessy, Fiona M.

AU - Zou, Kelly H.

AU - McDannold, Nathan

AU - Hynynen, Kullervo

AU - Jolesz, Ferenc A.

AU - Stewart, Elizabeth A

AU - Rybicki, Frank J.

AU - Tempany, Clare M.

PY - 2006/8

Y1 - 2006/8

N2 - Purpose: To determine whether the phase of menstrual cycle at the time of MR-guided focused ultrasound surgery (MRgFUS) treatment for uterine leiomyomas affects treatment outcome. Methods: We enrolled all patients participating in a prospective phase III clinical trial from our center who completed 6 months of clinical and imaging follow-up. Patients with irregular cycles and those on oral contraceptives were excluded. Data prospectively documenting the date of the last menstrual period (LMP) at the time of treatment, length and duration of cycle, and raw symptom severity score (SSS) from the Uterine Fibroid Symptom and Quality of Life questionnaire, at baseline and 6 months were collected. Proliferative phase patients were determined retrospectively as those who were treated within less than 14 days from LMP; secretory phase patients were classified as those who were treated greater than 14 days from LMP. Results: A total of 58 patients were enrolled. There was no significant difference in the mean SSS at baseline and mean SSS at 6 months between patients treated in the proliferative versus secretory phase of the cycle. No significant difference in the SSS change from baseline to 6 months was seen between the two groups. Conclusions: Menstrual cycle phase does not influence MRgFUS treatment outcome. Symptomatic improvement occurs with treatment during either phase of the menstrual cycle. Thus, the scheduling of MRgFUS treatment need not be based upon the phase of the menstrual cycle.

AB - Purpose: To determine whether the phase of menstrual cycle at the time of MR-guided focused ultrasound surgery (MRgFUS) treatment for uterine leiomyomas affects treatment outcome. Methods: We enrolled all patients participating in a prospective phase III clinical trial from our center who completed 6 months of clinical and imaging follow-up. Patients with irregular cycles and those on oral contraceptives were excluded. Data prospectively documenting the date of the last menstrual period (LMP) at the time of treatment, length and duration of cycle, and raw symptom severity score (SSS) from the Uterine Fibroid Symptom and Quality of Life questionnaire, at baseline and 6 months were collected. Proliferative phase patients were determined retrospectively as those who were treated within less than 14 days from LMP; secretory phase patients were classified as those who were treated greater than 14 days from LMP. Results: A total of 58 patients were enrolled. There was no significant difference in the mean SSS at baseline and mean SSS at 6 months between patients treated in the proliferative versus secretory phase of the cycle. No significant difference in the SSS change from baseline to 6 months was seen between the two groups. Conclusions: Menstrual cycle phase does not influence MRgFUS treatment outcome. Symptomatic improvement occurs with treatment during either phase of the menstrual cycle. Thus, the scheduling of MRgFUS treatment need not be based upon the phase of the menstrual cycle.

KW - Fibroids

KW - Focused ultrasound

KW - Leiomyomas

KW - Menstrual cycle

KW - MRgFUS

UR - http://www.scopus.com/inward/record.url?scp=33746242228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746242228&partnerID=8YFLogxK

U2 - 10.1016/j.ejrad.2006.05.004

DO - 10.1016/j.ejrad.2006.05.004

M3 - Article

C2 - 16766153

AN - SCOPUS:33746242228

VL - 59

SP - 203

EP - 207

JO - Journal of Medical Imaging

JF - Journal of Medical Imaging

SN - 0720-048X

IS - 2

ER -